Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications.
about
Efficient hepatic delivery of drugs: novel strategies and their significanceCell entry of one-dimensional nanomaterials occurs by tip recognition and rotationLocal targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicinSustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid.Ganglioside embedded in reconstituted lipoprotein binds cholera toxin with elevated affinityLactosaminated mesoporous silica nanoparticles for asialoglycoprotein receptor targeted anticancer drug delivery.Physico-chemical characterization of polylipid nanoparticles for gene delivery to the liver.Evaluation of pullulan-functionalized doxorubicin nanoparticles for asialoglycoprotein receptor-mediated uptake in Hep G2 cell line.Chitosan-DNA nanoparticles delivered by intrabiliary infusion enhance liver-targeted gene deliveryAnti-tumor effects of brucine immuno-nanoparticles on hepatocellular carcinomaA novel carbon monoxide-releasing molecule fully protects mice from severe malariaDynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes.Receptor binding characteristics and cytotoxicity of insulin-methotrexate.PEG-b-PPA/DNA micelles improve transgene expression in rat liver through intrabiliary infusion.ASGR1 and ASGR2, the Genes that Encode the Asialoglycoprotein Receptor (Ashwell Receptor), Are Expressed in Peripheral Blood Monocytes and Show Interindividual Differences in Transcript ProfileLactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infectionComparative in silico-in vivo evaluation of ASGP-R ligands for hepatic targeting of curcumin Gantrez nanoparticles.Antioxidant enzyme gene transfer for ischemic diseases.Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate.Lipid-based nanotherapeutics for siRNA deliveryReceptor-targeted nanocarriers for therapeutic delivery to cancer.Surface-bound cytomimetic assembly based on chemoselective and biocompatible immobilization and further modification of intact liposome.RNA interference in the treatment of renal stone disease: Current status and future potentials.Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus.A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay developmentMolecular therapy for hepatic injury and fibrosis: where are we?Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.Antitumor effects of brucine immuno-nanoparticles on hepatocellular carcinoma in vivo.
P2860
Q27007518-D486AA19-657F-403F-B39C-24A06D53A570Q28393643-319A8BC0-EA10-4D77-A68C-B5E030BB3A0AQ28533299-C0D8D618-EB19-4C38-B9A5-9527F142E054Q33985941-CB4EC7EC-8B0E-420B-9468-5023AFAAD7B1Q34053156-23B9893F-80F2-499D-933B-9DB92F9EEA4DQ35099618-5B5F9C96-801C-4605-8CC8-4052AD3AB4CBQ35114993-D86F74E3-1FF8-410D-AECF-02EF0BD39B84Q35673292-6B8AE25D-68CB-4F44-813A-E731A2EA23F3Q35688220-D9CF08EC-777D-4879-996F-360CC85CA956Q35741034-1405981A-9DFF-49F6-82A8-A12B1A23D8B6Q35806274-20D5E21A-2C11-4FF4-ABEE-0F2ACA7F085DQ35928850-6497CF76-C6E0-4789-908A-D653A2AA0849Q36076603-9AC3C678-12BB-44F3-A043-54A173A3058CQ36084329-13815658-CA64-40C8-80D4-48B28252950CQ36165181-EDFB4C01-FCED-47B6-A5A4-2990BF3294F2Q36334145-F17FB3AB-690A-437D-9221-2340553F2E2AQ36883851-1184830E-6C5D-4F42-9BDB-04AB796DA0F5Q36951909-F156C667-84A0-4F9E-860A-39F2ED0474CDQ37398189-D59BA2BF-F2BC-49EA-805D-4B57E871F048Q37442399-2CA438D3-98AA-42B0-A744-41F40D8549A4Q37670986-0E7A59AA-AB39-4E8C-859D-AD4A8FEF5C90Q37804383-8876900A-162B-40A6-9EDF-D1B1607ADC0DQ38340208-8468DA1E-FDD2-47A5-A398-C7FDC3A0FF37Q38795112-6F1F2257-8E57-41A3-BAF0-ACD965EC05D5Q38811832-BDD2D483-E470-434B-A169-FDE7B6178F46Q39586687-39D39F7A-D71D-4606-987F-E744B9F2E86EQ40213399-0B9DDD55-D0DE-432E-9F24-7C0FCAAE95B5Q41120756-5415B449-2341-46BC-994A-3E7DD3DFF8F7Q42704568-2094CDE3-313C-4D8B-88F1-22178DB926D2Q51165860-AC2D16DA-513A-4B5E-ABA3-DE48ECC11440Q54964792-79F0D0E0-8A39-4528-B89F-CF38D6FF1B1C
P2860
Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Targeting hepatocytes for drug ...... l approaches and applications.
@ast
Targeting hepatocytes for drug ...... l approaches and applications.
@en
Targeting hepatocytes for drug ...... l approaches and applications.
@nl
type
label
Targeting hepatocytes for drug ...... l approaches and applications.
@ast
Targeting hepatocytes for drug ...... l approaches and applications.
@en
Targeting hepatocytes for drug ...... l approaches and applications.
@nl
prefLabel
Targeting hepatocytes for drug ...... l approaches and applications.
@ast
Targeting hepatocytes for drug ...... l approaches and applications.
@en
Targeting hepatocytes for drug ...... l approaches and applications.
@nl
P2093
P356
P1476
Targeting hepatocytes for drug ...... l approaches and applications.
@en
P2093
Mark A Zern
Michael H Nantz
P304
P356
10.2741/A806
P577
2002-03-01T00:00:00Z